Imidazopyridines: A novel class of hNav1.7 channel blockers

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 5, 2008, Pages 1696-1701

  London, Clare ^a   Hoyt, Scott B ^a   Parsons, William H ^a   Williams, Brande S ^a   Warren, Vivien A ^a   Tschirret Guth, Richard ^a   Smith, McHardy M ^a   Priest, Birgit T ^a   McGowan, Erin ^a   Martin, William J ^a   Lyons, Kathryn A ^a   Li, Xiaohua ^a   Karanam, Bindhu V ^a   Jochnowitz, Nina ^a   Garcia, Maria L ^a   Felix, John P ^a   Dean, Brian ^a   Abbadie, Catherine ^a   Kaczorowski, Gregory J ^a   Duffy, Joseph L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

hNav1.7; Neuropathic pain; Sodium channel blockers; Voltage gated sodium channels

Indexed keywords

1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; CYTOCHROME P450 3A4; IMIDAZOPYRIDINE DERIVATIVE; SODIUM CHANNEL BLOCKING AGENT;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; NERVE LIGATION; NEUROPATHIC PAIN; NONHUMAN; RAT; RAT STRAIN; SPINAL NERVE;

ANALGESICS; ANIMALS; INFLAMMATION; MOLECULAR STRUCTURE; PAIN; PYRIDINES; RATS; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 39849107766     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.01.047     Document Type: Article

References (16)

1. Taylor R.S. Pain Pract. 6 (2006) 22
2. Butera J.A. J. Med. Chem. 50 (2007) 2544
3. Priest B.T., and Kaczorowski G.J. Expert Opin. Ther. Targets 11 (2007) 291
4. Anger T., Madge D.J., Mulla M., and Riddal D. J. Med. Chem. 44 (2001) 115
5. Cox J.J., Reimann F., Nicholas A.K., Thornton G., Roberts E., Springell K., Karbani G., Jafri H., Mannan J., Raashid Y., Al-Gazali L., Hamamy H., Valente E.M., Gorman S., Williams R., McHale D.P., Wood J.N., Gribble F.M., and Woods C.G. Nature 444 (2006) 894
6. Goldberg Y.P., MacFarlane J., MacDonald M.L., Thompson J., Dube M.-P., Mattice M., Fraser R., Young C., Hossain S., Pape T., Payne B., Radomski C., Donaldson G., Ives E., Cox J., Younghusband H.B., Green R., Duff A., Boltshauser E., Grinspan G.A., Dimon J.H., Sibley B.G., Andria G., Toscano E., Kerdraon J., Bowsher D., Pimstone S.N., Samuels M.E., Sherrington R., and Hayden M.R. Clin. Genet. 71 (2007) 311
7. Amir R., Argoff C.E., Bennett G.J., Cummins T.R., Durieux M.E., Gerner P., Gold M.S., Porreca F., and Strichartz G.R. J. Pain 7 Suppl. 1 (2006) S1
8. Jarvis M.F., Honore P., Shieh C., Chapman M., Joshi S., Zhang X., Kort M., Carroll W., Marron B., Atkinson R., Thomas J., Liu D., Krambis M., Liu Y., McGaraughty S., Chu K., Roeloffs R., Zhong C., Mikusa J.P., Hernandex G., Gauvin D., Wade C., Zhu C., Pai M., Scanio M., Shi L., Drizin I., Gregg R., Matulenko M., Hakeem A., Gross M., Johnson M., Marsh K., Wagoner P.K., Sullivan J.P., Faltynek C.R., and Krafte D.S. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 8250
9. Felix J.P., Williams B.S., Priest B.T., Brochu R.M., Dick I.E., Warren V.A., Yan L., Slaughter R.S., Kaczorowski G.J., Smith M.M., and Garcia M.L. Assay Drug Dev. Technol. 2 (2004) 260
10. Hoyt S.B., London C., Ok H., Gonzalez E., Duffy J.L., Weber A.E., Abbadie C., Felix J.P., Garcia M.L., Jochnowitz N., Li X., Lyons K.A., McGowan E., MacIntyre D.E., Martin W.J., Smith M.M., Warren V.A., Williams B.S., Kazorowski G.J., and Parsons W.H. Bioorg. Med. Chem. Lett. (2007) 6172
11. Hoyt S.B., London C., Gorin D., Wyvratt M.J., Fisher M.H., Abbadie C., Felix J.P., Garcia M.L., Li X., Lyons K.A., McGowan E., MacIntyre D.E., Martin W.J., Priest B.T., Ritter A., Smith M.M., Warren V.A., Williams B.S., Kaczorowski G.J., and Parsons W.H. Bioorg. Med. Chem. Lett. (2007) 4630
12. Schollkopf U. Tetrahedron 39 (1983) 2085
13. Wang J., Della Penna K., Wang H., Karczewski J., Connolly T.M., Koblan K.S., Bennett P.B., and Salata J.J. Am. J. Physiol. Heart Circ. Physiol. 284 (2002) H256
14. Rat PK experiments were conducted as follows: Test compounds were typically formulated as 1.5 mg/mL solutions in mixtures of PEG300/water or DMSO/PEG300/water. Fasted male Sprague-Dawley rats were given either a 1.0 mg/kg iv dose of test compound solution via a cannula implanted in the femoral vein or a 3.0 mg/kg po dose by gavage (n = 2 iv, 3 po). Serial blood samples were collected at 5 (iv only), 15 and 30 min, and at 1, 2, 4, 6, 8, and 24 h post-dose. Plasma was collected by centrifugation, and plasma concentrations determined by LC-MS/MS following protein precipitation with acetonitrile.
15. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., and Yakash T.L. J. Neurosci. Methods 53 (1994) 55
16. Colpaert F.C., Meert T., and De Witte P. Life Sci. 31 1 (1982) 67-75